CSI Market
Sign In | Register

Keenova Therapeutics Plc (MNK) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access MNK quarterly Cash Flow →
Cash flow performance over multiple periods helps investors evaluate the stability of Keenova Therapeutics Plc's cash-generating activities.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 29 2023) (Dec 30 2022)
Operating Activities
Income-39.00
Depreciation & amortization15.30
Amortization of Other Assets0.00
Accretion Expense0.00
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability3.50
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase38.50
R & D, Environmental and Other Expense0.00
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal0.00
Share-based Compensation0.00
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Increasedecrease Opioidrelatedlitigationsettlementliability-
Increase Decrease Opioid Related Litigation Settlement Liability-
Inventory Step Up Amortization Related To Business Combination-
Inventory Step Up Amortization From Acquisitions-
Reorganization Items Noncash-
Amortization Accretion Expense On Debt Premium Discount And Settlement Obligation-0.70
Increase Decrease In Accrued Consulting-6.80
Increase Decrease Acthar Gel Related Litigation Settlement-
Income taxes-3.50
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable21.30
Increase (Decrease) in Accounts Payable7.60
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities0.00
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets0.00
Other Working Capital33.40
Other Noncash Income (Expense)5.50
Other net0.00
Payments for (Proceeds from) Other Operating Activities-106.70
Discontinued operations105.00
Net Cash flow from Operating Activities73.40
Investing Activities
Capital Expenditures-2.20
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash Acquired From Business Acquisition-
Payments From Divestiture Of Business-
Proceeds from Sale of Restricted Investments0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Cash Acquired from Acquisition0.00
Interest in Subsidiaries and Affiliates0.00
Proceeds from Divestiture of Businesses, Net of Cash Divested0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.90
Other Net6.30
Discontinued operations-6.30
Net Cash Flow from Investing Activities-1.30
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings-102.20
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-916.90
Cash Cash Equivalents and Restricted Cash Period Increase Decrease-
Cash and Cash Equivalents Including Restricted Cash Period End-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents300.10
Restricted Cash And Investments Current-
Restricted Cash And Investments Noncurrent-
Payments For Settlement Of Opioid Contingent Value Rights-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations273.40
Cash And Cash Equivalent Including Discontinued Operation262.70
Restricted Cash Current Including Discontinued Operations40.80
Restricted Cash Noncurrent Including Discontinued Operations39.90
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-102.20
Effect of exchange rate on cash flow1.40
Discontinued operations98.70
Free Cash Flow71.20
Total Cash Flow70.00
4 historic quarters locked

Sign in to unlock the full Keenova Therapeutics Plc cash flow history.

Sign In Create Free Account

About Keenova Therapeutics Plc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: April 15, 2026
  • Source: mnk-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001628280-26-025238

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License